Inventor · disambiguated record
Mark Pruzanski
Also filed as: PRUZANSKI MARK
15 granted patents·11 pending applications·117 citations·filing 2005–2025
92Inventor score
Top patents by PatentIndex Score
26 records- 0196US9763964B2Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditionsINTERCEPT PHARMACEUTICALS INC·Filed 2015·Granted Sep 19, 2017·23 cites·7 claims
- 0294US7932244B2Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditionsINTERCEPT PHARMACEUTICALS INC·Filed 2007·Granted Apr 26, 2011·24 cites·8 claims
- 0393US10052337B2Compositions of obeticholic acid and methods of useINTERCEPT PHARMACEUTICALS INC·Filed 2016·Granted Aug 21, 2018·21 cites·19 claims
- 0492US7858608B2Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditionsINTERCEPT PHARMACEUTICALS INC·Filed 2009·Granted Dec 28, 2010·21 cites·5 claims
- 0589US8546365B2Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditionsPELLICCIARI ROBERTO·Filed 2011·Granted Oct 1, 2013·10 cites·18 claims
- 0687US10758549B2Compositions of obeticholic acid and methods of useINTERCEPT PHARMACEUTICALS INC·Filed 2020·Granted Sep 1, 2020·2 cites·33 claims
- 0785US10894054B2FXR agonist compositions for combination therapyINTERCEPT PHARMACEUTICALS INC·Filed 2016·Granted Jan 19, 2021·3 cites·8 claims
- 0884US9498484B2Treatment of fibrosis using FXR ligandsFIORUCCI STEFANO·Filed 2005·Granted Nov 22, 2016·8 cites·8 claims
- 0983US10646499B2Compositions of obeticholic acid and methods of useINTERCEPT PHARMACEUTICALS INC·Filed 2018·Granted May 12, 2020·1 cites·20 claims
- 1081US9090652B2Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditionsINTERCEPT PHARMACEUTICALS INC·Filed 2013·Granted Jul 28, 2015·3 cites·9 claims
- 1178US2025367217A1Pharmaceutical compositions for combination therapyINTERCEPT PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1278US2025367216A1Pharmaceutical compositions for combination therapyINTERCEPT PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1377US12337003B2Pharmaceutical compositions for combination therapyINTERCEPT PHARMACEUTICALS INC·Filed 2022·Granted Jun 24, 2025·0 cites·18 claims
- 1477US11311557B2Pharmaceutical compositions for combination therapyINTERCEPT PHARMACEUTICALS INC·Filed 2016·Granted Apr 26, 2022·1 cites·16 claims
- 1575US2022133745A1Compositions of obeticholic acid and methods of useINTERCEPT PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1674US10751349B2Compositions of obeticholic acid and methods of useINTERCEPT PHARMACEUTICALS INC·Filed 2019·Granted Aug 25, 2020·0 cites·22 claims
- 1770US10987362B2Treatment of fibrosis using FXR ligandsINTERCEPT PHARMACEUTICALS INC·Filed 2018·Granted Apr 27, 2021·0 cites·5 claims
- 1867US2020046736A1Compositions of obeticholic acid and methods of useINTERCEPT PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1967US2020046735A1Compositions of obeticholic acid and methods of useINTERCEPT PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2067US2020054650A1Compositions of obeticholic acid and methods of useINTERCEPT PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2162US2021346400A1Treatment of fibrosis using fxr ligandsINTERCEPT PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2254US2014148428A1Treatment of Pulmonary DiseaseINTERCEPT PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2351US10258633B2Treatment of fibrosis using FXR ligandsFIORUCCI STEFANO·Filed 2016·Granted Apr 16, 2019·0 cites·6 claims
- 2451US2018064729A1Treatment of Pulmonary DiseaseINTERCEPT PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2547US2016213689A1Treatment of Pulmonary DiseaseINTERCEPT PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2643US2006252670A1Method of reducing drug-induced adverse side effects in a patientINTERCEPT PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Pruzanski files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →